Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion PharmaceuticalsNSE:ACCPL +2.56%21 EV-to-EBITDA is 15.23 as of Aug. 19, 2026, which is 101% above its 10-year median of 7.56. GuruFocus rates NSE:ACCPL with a GF Score™ of 21/100. The stock has 6 warning signs investors should review. Among 734 Drug Manufacturers companies, Accretion Pharmaceuticals ranks worse than 55.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Accretion Pharmaceuticals's enterprise value is ₹2,306.2 Mil.
Accretion Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹151.4 Mil. Therefore, Accretion Pharmaceuticals's EV-to-EBITDA for today is 15.23.
The historical rank and industry rank for Accretion Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NSE:ACCPL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.54 Med: 7.56 Max: 15.23
Current: 15.23
During the past 5 years, the highest EV-to-EBITDA of Accretion Pharmaceuticals was 15.23. The lowest was 5.54. And the median was 7.56.
NSE:ACCPL's EV-to-EBITDA is ranked worse than 55.31% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.435
vs NSE:ACCPL: 15.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Accretion Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Accretion Pharmaceuticals's share price for today is ₹200.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accretion Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹9.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's EV-to-EBITDA falls into.
Accretion Pharmaceuticals's current Enterprise Value is ₹2,306.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accretion Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹151.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a EV-to-EBITDA of 15.23 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Accretion Pharmaceuticals. This is 101% above median its historical median of 7.56. Over the past decade, Accretion Pharmaceuticals' EV-to-EBITDA has ranged from 5.54 to 15.23. According to the industry distribution chart, Accretion Pharmaceuticals ranks #406 out of 734 companies in the Drug Manufacturers industry, placing it in the top 55.3%.
Is Accretion Pharmaceuticals' EV-to-EBITDA too high?
Accretion Pharmaceuticals' current EV-to-EBITDA of 15.23 is 101% above median its 10-year median of 7.56. Over the past 10 years, this metric has ranged from a low of 5.54 to a high of 15.23. The Drug Manufacturers industry median EV-to-EBITDA is 13.44. Accretion Pharmaceuticals' value of 15.23 is 13.4% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #406 out of 734 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #406 out of 734 companies for EV-to-EBITDA. This places Accretion Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.44. Accretion Pharmaceuticals' value of 15.23 is 13.4% above this benchmark. Historically, Accretion Pharmaceuticals' own EV-to-EBITDA has ranged from 5.54 to 15.23 over the past decade. While the company's 10-year median is 7.56 vs. the industry median of 13.44, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.44, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current EV-to-EBITDA of 15.23 is 13.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Accretion Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current EV-to-EBITDA is 15.23, which is 101% above median its own 10-year median of 7.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current EV-to-EBITDA of 15.23. The current EV-to-EBITDA is 15.23, which is 101% above median its 10-year median of 7.56 and 13.4% above the Drug Manufacturers industry median of 13.44. Accretion Pharmaceuticals' overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current EV-to-EBITDA is 15.23 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
21GF Score
Get the complete analysis for NSE:ACCPL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 
